IDEAYA Biosciences (NASDAQ: IDYA) reported data from a phase 1/2 trial testing its experimental drug IDE397 combined with Gilead's Trodelvy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE